ブレイアコニチンA

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H300：飲み込むと生命に危険

  H330：吸入すると生命に危険

• 注意書き

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P271：屋外または換気の良い場所でのみ使用すること。

  P284：呼吸用保護具を着用すること。

  P301+P310：飲み込んだ場合：直ちに医師に連絡すること。

  P304+P340：吸入した場合：空気の新鮮な場所に移し、呼吸しやすい 姿勢で休息させること。

  P310：ただちに医師に連絡すること。

  P320：特別な治療が緊急に必要である（このラベ ルの．．．を見よ）。

  P321：特別な処置が必要である（このラベルの．．． を見よ）。

  P330：口をすすぐこと。

  P403+P233：換気の良い場所で保管すること。容器を密閉 しておくこと。

  P405：施錠して保管すること。

  P501：内容物/容器を．．．に廃棄すること。

ブレイアコニチンA 価格

ブレイアコニチンA 化学特性,用途語,生産方法

• 説明

  Bulleyaconitine A is an aconitine-type two terpene alkaloid, and its molecular formula is C35H49NO10.?As early as 1980, bulleyaconitine was separated and extracted from a traditional analgesic and anti-inflammatory herb in the west of Yunnan called dianxi dula (or dianxi wutou) (Aconitum bulleyanum Diels), by the Kunming Institute of Botany, Chinese Academy of Sciences . At present, bulleyaconitine A can be separated from Aconitum plants, for example, dianxi wutou (Aconitum bulleyanum Diels), cujing wutou (Aconitum crassicaule W.T.?Wang), changhui wutou (Aconitum georgei Comber), and zhiyuan wutou (Aconitum transsectum Diels).

• 物理的性質

  Appearance: white powder. Solubility: soluble in methanol, ethanol, chloroform, and ether; insoluble in water; and easily dissolved in dilute hydrochloric acid or dilute sulfuric acid . Melting point: 160–165?°C

• 来歴

  In 1983, it was confirmed that bulleyaconitine A shows obvious analgesic and antiinflammatory effects by preclinical pharmacological tests . Clinical trials were carried out in 29 hospitals in 9 provinces in 1984. Bulleyaconitine A passed technical appraisals in May 1985 and was first formally put into production by Yunnan Honghe Pingbian pharmaceutical company, where it obtained the trade name “Bulleyaconitine A.” Bulleyaconitine A has been listed into the Pharmacopoeia of the People’s Republic of China (2015). In recent years, bulleyaconitine A has shown a great market growth and competitive power, owing to its exact curative effect and rapid clinical promotion in chronic disease and rheumatic immune disease.

• 臨床応用

  1. Rheumatic immune disease. Since listing, bulleyaconitine A has been applied in clinical treatment for rheumatoid arthritis and osteoarthritis, receiving good curative effects.
  2. Chronic pain. Bulleyaconitine A does not belong to NSAID, and it exerts its effects by regulating the sodium ion channel. So there is little psychological dependence and organ toxicity, avoiding gastrointestinal/cardiovascular/renal adverse reactions and drug dependence or other potential dangers caused by NSAID and opioid analgesics.

ブレイアコニチンA 生産企業

Global(196)Suppliers

107668-79-1, ブレイアコニチンA キーワード